111 related articles for article (PubMed ID: 38570733)
1. Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake.
Dai D; Yu J; Gou W; Yang S; Li Y; Wang Z; Yang Z; Huang T; Li P; Zhu T; Hou W; Zhao Y; Xu W; Li Y
J Med Chem; 2024 Apr; 67(8):6726-6737. PubMed ID: 38570733
[TBL] [Abstract][Full Text] [Related]
2. Improving the Imaging Contrast of
Baranski AC; Schäfer M; Bauder-Wüst U; Wacker A; Schmidt J; Liolios C; Mier W; Haberkorn U; Eisenhut M; Kopka K; Eder M
Bioconjug Chem; 2017 Sep; 28(9):2485-2492. PubMed ID: 28787147
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of new target CDK19 in prostate cancer.
Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
8. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
9. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
11. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
12. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
13. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
15. One-Step
Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F
J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299
[TBL] [Abstract][Full Text] [Related]
16. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
17. [
Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
20. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]